14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
PBE vs PBJ
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
PBE vs PBJ: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PBE Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 2–1 Matrix Metrics)
PBE Overall Winner
6-Pillar Tally: PBE 0 – 0 PBJ (6 Tie)
Matrix Metrics: PBE 2 – 1 PBJ
As of Nov 16, 2026, Invesco Biotechnology & Genome ETF (PBE) is the stronger overall head-to-head candidate over Invesco Food & Beverage ETF (PBJ) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). PBE carries a Unified Composite Score of 53.2/100 (HOLD) at $96.22 (N/M Forward P/E, N/A operating margin), whereas PBJ carries 47.7/100 (HOLD) at $48.07 (N/M Forward P/E, N/A operating margin).
PBE
NYSE Arca
Head-to-Head Winner
Invesco Biotechnology & Genome ETF
Institutional Equity
Market Cap
N/A
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.74β · 28% Vol
Unified Composite Score
53.2 / 100
HOLD
Tech 41.0
Fund 44.0
Flow 50.0
Mom 41.1
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 44
RSI-14: 44.1 · SMA20: $100.25 · SMA50: $97.48
PBJ
NYSE Arca
Invesco Food & Beverage ETF
Institutional Equity
Market Cap
N/A
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.06β · 22% Vol
Unified Composite Score
47.7 / 100
HOLD
Tech 48.0
Fund 47.0
Flow 50.0
Mom 41.1
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.0 · SMA20: $47.91 · SMA50: $46.91
6-Pillar Scorecard Institutional Category Breakdown (PBE 0 – 0 PBJ)
Columns: Metric · PBE · PBJ
1. Valuation Multiples
Tie
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
N/M
2. Growth & Scale
Tie
Revenue Growth (YoY)
N/A
N/A
Earnings Growth (YoY)
N/A
N/A
TTM Revenue (USD)
N/A
N/A
Market Cap
N/A
N/A
3. Profitability & Quality
Tie
Gross Margin
N/A
N/A
Operating Margin
N/A
N/A
Net Profit Margin
N/A
N/A
Return on Equity (ROE)
N/A
N/A
4. Balance Sheet & Cash Flow
Tie
Cash Generation (TTM)
N/A
N/A
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
N/A ROE
N/A ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
23.6% (<1st %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Institutional Equity Operator
Institutional Equity Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: PBE (2) vs PBJ (1)
Institutional Metric
PBE
PBJ
Criterion
Row Edge
Market Capitalization
Scale
N/A
N/A
Larger Scale
Tie
Trailing P/E Ratio
Valuation
N/M
N/M
Lower Multiple
Tie
Forward P/E Ratio
Valuation
N/M
N/M
Lower Multiple
Tie
Revenue Growth (YoY)
Growth
N/A
N/A
Higher Growth
Tie
Operating Margin (TTM)
Profitability
N/A
N/A
Higher Margin
Tie
Net Profit Margin
Profitability
N/A
N/A
Higher Margin
Tie
Return on Equity (ROE)
Capital Efficiency
N/A
N/A
Higher ROE
Tie
52-Week Range Position
Momentum
71% ($76–$105)
60% ($43–$51)
Stronger Trend
PBE
Beta / 30D Volatility
Risk Regime
0.74β · 28% Vol
0.06β · 22% Vol
Lower Realized Risk
PBJ
Unified Institutional Score
Composite Signal
53.2 / 100 (HOLD)
47.7 / 100 (HOLD)
Higher Composite
PBE
Trailing 12M Revenue (USD)
Operating Scale
N/A
N/A
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A
N/A
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev
N/M PEG · N/M EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE)
N/A (N/A ROE)
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
PBJ +0.7 pp
PBE:
+0.15%
·
PBJ:
+0.85%
3M Horizon
PBE +1.0 pp
PBE:
+0.99%
·
PBJ:
-0.01%
6M Horizon
PBE +20.66 pp
PBE:
+19.69%
·
PBJ:
-0.97%
1Y Horizon
PBE +14.66 pp
PBE:
+23.93%
·
PBJ:
+9.27%
Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)
Split-Invariant USD Revenue & Operating Margin (%)
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PBE vs PBJ. Trailing 12-month operating profitability (PBE N/A vs PBJ N/A) and valuation multiples (PBE N/M vs PBJ N/M Forward P/E) are benchmarked directly in Pillar 4 below.
PBE ADR TTM Benchmark
FX-Normalized USD
TTM Revenue N/A
Gross Margin N/A
Op. Margin N/A
ROE / Fwd P/E N/A · N/M
PBJ ADR TTM Benchmark
FX-Normalized USD
TTM Revenue N/A
Gross Margin N/A
Op. Margin N/A
ROE / Fwd P/E N/A · N/M
PBE
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
23.6%
IV Percentile
<1st %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
PBJ
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
PBE Moat Profile
Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
PBJ Moat Profile
Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ PBE vs PBJ Key Questions & Quantitative Answers
Is PBE or PBJ a better stock to buy right now?
As of Nov 16, 2026, Invesco Biotechnology & Genome ETF (PBE) is the stronger overall head-to-head candidate over Invesco Food & Beverage ETF (PBJ) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). PBE carries a Unified Composite Score of 53.2/100 (HOLD) at $96.22 (N/M Forward P/E, N/A operating margin), whereas PBJ carries 47.7/100 (HOLD) at $48.07 (N/M Forward P/E, N/A operating margin). Technically, PBE sits in a Neutral phase (RSI 44.1, UNCLASSIFIED options structure) and PBJ sits in a Neutral phase (RSI 54.0, UNCLASSIFIED options structure).
Does PBE or PBJ have stronger revenue and earnings growth?
PBE and PBJ split Growth & Scale metrics: PBE posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with PBJ at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, PBE generates N/A in USD-normalized revenue versus N/A for PBJ. In operating R&D and SG&A reinvestment, PBE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PBJ.
Is PBE or PBJ cheaper on valuation?
PBE and PBJ trade at balanced relative valuation multiples. PBE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PBJ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PBE (N/A ROE) versus PBJ (N/A ROE) capital efficiency.
How is options market volatility positioned on PBE vs PBJ?
In options market volatility and institutional positioning, PBE carries 23.6% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.74β · 28% Vol realized risk). By comparison, PBJ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.06β · 22% Vol realized risk).
Invesco Biotechnology & Genome ETF (PBE) Research Suite
Invesco Food & Beverage ETF (PBJ) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.